Ras
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB03771 | ZCL278 | 587841-73-4 | ZCL278 is a modulator of Cdc42 through directly binding to Cdc42 with Kd of 11.4 μM. |
| FB08115 | XRP44X | 729605-21-4 | XRP44X is an inhibitor of Ras-Net (Elk-3) pathway with IC50 of 10 nM - 20 nM and could inhibit the phosphorylation of ERK1/ERK2. |
| FB17720 | StRIP3 | 1589567-45-2 | StRIP3 is a hydrocarbon-stapled peptide targeting Rab proteins bound to their interaction partners. It selectively binds to activated Rab8a and inhibits a Rab8a–effector interaction in vitro. |
| FB04792 | Schisantherin A | 58546-56-8 | Schisantherin A is a natural product isolated and purified from the herbs of Chelidonium majus with anti-microbial, anti-oxidant and anti-inflammatory properties, and is a specific inhibitor of Rac1b. |
| FB17712 | SAH-SOS1A | 1652561-87-9 | SAH-SOS1A is a KRAS-targeting stapled peptide with EC50 values of 106, 109, 154, 140, 155 and 175nM for K-Ras, K-Ras (G12D), K-Ras (G12V), K-Ras (G12C), K-Ras (G12S) and K-Ras (Q61H), respectively. It disrupts the SOS1/KRAS protein interaction and directly inhibit nucleotide association to wild-type and mutant KRAS proteins. |
| FB00649 | RBC8 | 361185-42-4 | RBC8 is an inhibitor of GTPases RalA and RalB with IC50 of 3.5 μM in cell assay. |
| FB19608 | PROTAC K-Ras Degrader-1 | 2378258-52-5 | PROTAC K-Ras Degrader-1 (Compound 518) is a PROTAC targeting on K-Ras and exhibits ≥70% degradation efficacy in SW1573 cells. |
| FB07932 | Oncrasin-1 | 75629-57-1 | Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations and also leads to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells. |
| FB00028 | NSC 23766 3HCl | 1177865-17-6 | NSC23766 is identified to fit into a surface groove of Rac1 known to be critical for GEF specification. |
| FB10792 | NSC 23766 | 733767-34-5 | NSC 23766 is a specific inhibitor of the binding and activation of RAC GTPase with IC50 of ~50 μM and does not inhibit the closely related targets, Cdc42 or RhoA. |
| FB15512 | N-(2,6-Dioxopiperidin-3-yl)-2-phenylacetamide | 77658-84-5 | N-(2,6-Dioxopiperidin-3-yl)-2-phenylacetamide is the mixture of S- and R- form Antineoplaston A10, which is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer. |
| FB16456 | MRTX849 | 2326521-71-3 | MRTX849 is a potent, selective and covalent K-Ras (G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound K-Ras (G12C), and inhibits KRAS-dependent signaling. |
| FB16359 | MRTX1257 | 2206736-04-9 | MRTX1257 is a selective, covalent K-Ras G12C inhibitor with oral activity in animal models of cancer. |
| FB04135 | ML141 | 71203-35-5 | ML141 is a reversible and selective inhibitor of Cdc42 GTPase with IC50 of 200 nM. |
| FB06833 | MDK-3017 | 84783-01-7 | MDK-3017 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure. |
| FB10872 | MBQ-167 | 2097938-73-1 | MBQ-167 is a dual Rac and Cdc42 inhibitor, potential to be developed as an anticancer drug. |
| FB17542 | LC-2 | 2502156-03-6 | LC-2 is the first PROTAC capable of degrading endogenous KRAS(G12C). It covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines. |
| FB08808 | Kobe2602 | 454453-49-7 | Kobe2602 is an effective small-molecule compound inhibiting Ras–Raf interaction by SBDD exhibiting potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM. |
| FB08807 | Kobe0065 | 436133-68-5 | Kobe0065 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with Ki of 46 ± 13 μM. |
| FB06686 | K-Ras(G12C) Inhibitor 12 | 1469337-95-8 | K-Ras(G12C) inhibitor 12 belongs to a series of small molecules, which irreversibly bind to a common oncogenic mutant K-Ras(G12C) and blocks K-Ras(G12C) interactions. |
| FB03951 | K-Ras G12C-IN-3 | 1629268-19-4 | K-Ras G12C-IN-3 is an irreversible inhibitor of mutant K-ras G12C. |
| FB03950 | K-Ras G12C-IN-2 | 1629267-75-9 | K-Ras G12C-IN-2 is an irreversible inhibitor of mutant K-ras G12C. |
| FB03949 | K-Ras G12C-IN-1 | 1629265-17-3 | K-Ras G12C-IN-1 is an irreversible inhibitor of mutant K-ras G12C. |
| FB08633 | EHT 1864 | 754240-09-0 | EHT 1864 2HCl is an inhibitor of Rac1 (Kd = 40 nM), Rac1b (Kd = 50 nM), Rac2 (Kd = 60 nM) and Rac3 (Kd = 250 nM). |
| FB01121 | EHop-016 | 1380432-32-5 | EHop-016 is an inhibitor of Rac1 with IC50 of 1.1 μM in MDA-MB-435 cells. |
| FB16511 | CID 1067700 | 314042-01-8 | CID-1067700 is a potent and competitive inhibitor of Ras-related GTPases inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM. |
| FB01593 | CASIN | 425399-05-9 | CASIN is an inhibitor of GTPase Cdc42 with IC50 of 2 μM that can generat a rejuvenated phenotype of HSCs. |
| FB00637 | BQU57 | 1637739-82-2 | BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. |
| FB16540 | BI-2852 | 2375482-51-0 | BI-2852 is a KRAS(G12C) inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity, with IC50 of 450 nM. |
| FB07877 | Azathioprine | 446-86-6 | Azathioprine can inhibit GTP-binding protein Rac1 activation and purine synthesis. Azathioprine is used to treat organ transplantation and autoimmune diseases. |
| FB10295 | ARS-853 | 1629268-00-3 | ARS-853 is an inhibitor of KRAS G12C with IC50 of 2.5 μM. |
| FB11633 | ARS-1630 | 1698055-86-5 | ARS-1630 is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. |
| FB11543 | ARS-1620 | 1698055-85-4 | ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. |
| FB11562 | ARS-1323 | 1698024-73-5 | ARS-1323 is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. |
| FB15513 | Antineoplaston A10 | 91531-30-5 | Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer. |
| FB15653 | AMG 510 | 2296729-00-3 | AMG-510 is a potent, orally bioavailable, and selective KRAS G12C covalent inhibitor, which locks KRAS G12C in an inactive GDP-bound state. AMG-510 selectively targets the KRAS p.G12C mutant and shows anti-tumor activity. |
| FB10278 | 6H05 Trifluoroacetate | 2061344-88-3 | 6H05 trifluoroacetate is a selective, and allosteric inhibitor of oncogenic mutant K-Ras (G12C). |
| FB03256 | 6H05 | 1469338-01-9 | 6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras (G12C). |
| FB15681 | 1A-116 | 1430208-73-3 | 1A-116 is a specific Rac1 inhibitor. |